These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 24678017

  • 1. Donor-specific alloantibodies are associated with fibrosis progression after liver transplantation in hepatitis C virus-infected patients.
    O'Leary JG, Kaneku H, Jennings L, Susskind BM, Terasaki PI, Klintmalm GB.
    Liver Transpl; 2014 Jun; 20(6):655-63. PubMed ID: 24678017
    [Abstract] [Full Text] [Related]

  • 2. Non-HLA Antibodies Impact on C4d Staining, Stellate Cell Activation and Fibrosis in Liver Allografts.
    OʼLeary JG, Demetris AJ, Philippe A, Freeman R, Cai J, Heidecke H, Smith C, Hart B, Jennings LW, Catar R, Everly M, Klintmalm GB, Dragun D.
    Transplantation; 2017 Oct; 101(10):2399-2409. PubMed ID: 28665894
    [Abstract] [Full Text] [Related]

  • 3. Preformed class II donor-specific antibodies are associated with an increased risk of early rejection after liver transplantation.
    O'Leary JG, Kaneku H, Jennings LW, Bañuelos N, Susskind BM, Terasaki PI, Klintmalm GB.
    Liver Transpl; 2013 Sep; 19(9):973-80. PubMed ID: 23780820
    [Abstract] [Full Text] [Related]

  • 4. Prevalence, Risk Factors, and Impact of Donor-Specific Alloantibodies After Adult Liver Transplantation.
    Vandevoorde K, Ducreux S, Bosch A, Guillaud O, Hervieu V, Chambon-Augoyard C, Poinsot D, André P, Scoazec JY, Robinson P, Boillot O, Dubois V, Dumortier J.
    Liver Transpl; 2018 Aug; 24(8):1091-1100. PubMed ID: 29665189
    [Abstract] [Full Text] [Related]

  • 5. Explanted liver inflammatory grade predicts fibrosis progression in hepatitis C recurrence.
    Ghabril M, Dickson RC, Krishna M, Machicao V, Aranda-Michel J, Bonatti H, Nguyen JH.
    Liver Transpl; 2011 Jun; 17(6):685-94. PubMed ID: 21618689
    [Abstract] [Full Text] [Related]

  • 6. Angiotensin blockade does not affect fibrosis progression in recurrent hepatitis C after liver transplantation.
    Guillaud O, Gurram KC, Puglia M, Lilly L, Adeyi O, Renner EL, Selzner N.
    Transplant Proc; 2013 Jun; 45(6):2331-6. PubMed ID: 23953545
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Pretransplant donor-specific anti-HLA antibodies as predictors of early allograft rejection in ABO-compatible liver transplantation.
    Musat AI, Pigott CM, Ellis TM, Agni RM, Leverson GE, Powell AJ, Richards KR, D'Alessandro AM, Lucey MR.
    Liver Transpl; 2013 Oct; 19(10):1132-41. PubMed ID: 23873778
    [Abstract] [Full Text] [Related]

  • 9. Pretransplant donor-specific HLA antibodies detected by single antigen bead flow cytometry: risk factors and outcomes after kidney transplantation.
    Kanter Berga J, Sancho Calabuig A, Gavela Martinez E, Puig Alcaraz N, Beltran Catalan S, Avila Bernabeu A, Crespo Albiach J, Montoro JA, Pallardo Mateu LM.
    Transplant Proc; 2012 Nov; 44(9):2529-31. PubMed ID: 23146444
    [Abstract] [Full Text] [Related]

  • 10. A 7-gene signature of the recipient predicts the progression of fibrosis after liver transplantation for hepatitis C virus infection.
    do O NT, Eurich D, Schmitz P, Schmeding M, Heidenhain C, Bahra M, Trautwein C, Neuhaus P, Neumann UP, Wasmuth HE.
    Liver Transpl; 2012 Mar; 18(3):298-304. PubMed ID: 22139994
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. De novo donor-specific anti-HLA antibodies mediated rejection in liver-transplant patients.
    Del Bello A, Congy-Jolivet N, Danjoux M, Muscari F, Lavayssière L, Esposito L, Cardeau-Desangles I, Guitard J, Dörr G, Milongo D, Suc B, Duffas JP, Alric L, Bureau C, Guilbeau-Frugier C, Rostaing L, Kamar N.
    Transpl Int; 2015 Dec; 28(12):1371-82. PubMed ID: 26303035
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Outcome of recurrent hepatitis C virus after liver transplantation in a randomized trial of tacrolimus monotherapy versus triple therapy.
    Manousou P, Samonakis D, Cholongitas E, Patch D, O'Beirne J, Dhillon AP, Rolles K, McCormick A, Hayes P, Burroughs AK.
    Liver Transpl; 2009 Dec; 15(12):1783-91. PubMed ID: 19938143
    [Abstract] [Full Text] [Related]

  • 17. Killer cell immunoglobulin-like receptor genotype and killer cell immunoglobulin-like receptor-human leukocyte antigen C ligand compatibility affect the severity of hepatitis C virus recurrence after liver transplantation.
    de Arias AE, Haworth SE, Belli LS, Burra P, Pinzello G, Vangeli M, Minola E, Guido M, Boccagni P, De Feo TM, Torelli R, Cardillo M, Scalamogna M, Poli F.
    Liver Transpl; 2009 Apr; 15(4):390-9. PubMed ID: 19326408
    [Abstract] [Full Text] [Related]

  • 18. Transforming growth factor β1 polymorphisms and progression of graft fibrosis after liver transplantation for hepatitis C virus--induced liver disease.
    Eurich D, Bahra M, Boas-Knoop S, Lock JF, Golembus J, Neuhaus R, Neuhaus P, Neumann UP.
    Liver Transpl; 2011 Mar; 17(3):279-88. PubMed ID: 21384510
    [Abstract] [Full Text] [Related]

  • 19. Effects of ethnicity and socioeconomic status on survival and severity of fibrosis in liver transplant recipients with hepatitis C virus.
    Verna EC, Valadao R, Farrand E, Pichardo EM, Lai JC, Terrault NA, Brown RS.
    Liver Transpl; 2012 Apr; 18(4):461-7. PubMed ID: 22467547
    [Abstract] [Full Text] [Related]

  • 20. Serum chemokine CXC ligand 10 (CXCL10) predicts fibrosis progression after liver transplantation for hepatitis C infection.
    Berres ML, Trautwein C, Schmeding M, Eurich D, Tacke F, Bahra M, Neuhaus P, Neumann UP, Wasmuth HE.
    Hepatology; 2011 Feb; 53(2):596-603. PubMed ID: 21274880
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.